

# **Corporate Update**

- Reminder on the terms for exercising redeemable share purchase warrants (BSAR)
- Laurence Géricot joins the Europlasma Group as Chief Financial Officer
- Europlasma has joined the EnterNext PEA-PME 150 index

**Europlasma, a French manufacturer with international reach, designing and using plasma solutions to produce renewable energy and recover hazardous waste,** reminds the terms for exercising the redeemable share purchase warrants (BSAR) issued by the company on 6 November 2014, announces the appointment of a new Chief Financial Officer, and announces that the Europlasma Group has joined the EnterNext PEA-PME 150 index.

 Reminder on the characteristics of and terms for exercising redeemable share purchase warrants (BSAR)

Following the capital increase launched on 24 September 2014, the company issued and granted to each shareholder two classes of BSAR warrants listed on Alternext Euronext Paris.

# Characteristics:

BSAR A (ISIN FR0012160653): Two BSAR A warrants entitle holders to subscribe for one new share at €0.80 per share, for a period of three years from 6 November 2014.

BSAR B (ISIN FR0012160661): Four BSAR B warrants entitle holders to subscribe for one new share at €1.30 per share, for a period of five years from 6 November 2014.

Subscribing for new shares through the exercise of BSAR warrants entitles the holder to an ISF (French solidarity tax on wealth) reduction of up to 50% of the invested amount. This reduction is capped at €45,000 and subject to French tax regulations.

# Terms of exercise:

In order to exercise their BSAR, holders should send their subscription instructions with payment of the corresponding exercise price to their intermediary custodian.

Caceis Corporate Trust, will ensure the centralisation and execution of these operations within two working days.

The new shares resulting from the exercise of BSAR A and BSAR B will be subject to periodic requests for admission to trading on Alternext Euronext Paris and will be listed under the same ISIN code as existing shares of the company, i.e. FR0000044810.

# • Appointment of Laurence Géricot as Chief Financial Officer

Laurence Géricot has been newly appointed as the Group's Chief Financial Officer by the Europlasma Board of Directors to replace Estelle Mothay, who decided to give new impetus to her career. The Board of Directors thanks Estelle for her contribution and commitment over the last four years.

Laurence began her career at Hewlett Packard in 1988 with various high-level operational and financial positions in France and abroad (including three years at the head office in California).

In 2006, she joined the field of biotechnologies as Deputy CEO responsible for the finances of Biomedical Diagnostic. From 2010 to 2014, she completed several operations in finance, management and consulting for innovative companies (including Nanobiotix listed on Euronext Paris) before joining the Europlasma Group. Laurence is a graduate from ESSEC Business School (MBA Grande Ecole).

# Europlasma joins the EnterNext PEA-PME 150 index

Europlasma has been included in the PEA-PME 150 index, which comprises 150 PEA-eligible French companies listed on the Euronext or Alternext markets in Paris. This new index represents a benchmark for investors, with 150 listed companies across all sectors and forming part of 80% of the most liquid PEA-PME eligible assets.

Jean-Eric Petit made the following statement: "Joining a benchmark index should increase our visibility among French and foreign investors and develop the liquidity of our shares, although they have accelerated over the last few days, no doubt as a result of our latest capital increase. During the trading session of 13 November 2014, 24,575,980 shares (i.e. 36% of capital) were traded, thereby showing the strong interest of investors in the Group's shares. It should be noted that no threshold crossing was declared to the company within the statutory period of five trading days from the session."

#### About Europlasma

Europlasma, the French company with a global reach that designs, builds and operates plasma solutions for renewable energy generation and hazardous waste recovery. Founded in 1992 to apply its proprietary plasma torch technology to hazardous waste destruction, it is now built on the following three business units:

- Europlasma is in charge of developing, constructing and operating various industrial processes using plasma technology;
- **CHO Power** is a supplier and operator of waste and biomass power plants by advanced gasification;
- Inertam is the global specialist in the destruction and recycling of asbestos and hazardous waste.

http://www.europlasma.com [Alternext - NYSE Euronext Paris – Mnemo : ALEUP – Isin : FR0000044810]

EUROPLASMA Jean- Éric PETIT - CEO Laurence GÉRICOT - CFO Anne BORDERES – Shareholders & investors contact Tel: + 33 (0) 556 497 000 / <u>contactbourse@europlasma.com</u>